| Identification | Back Directory | [Name]
Valsartan D9 | [CAS]
1089736-73-1 | [Synonyms]
[2H9]-Valsartan
rac-Valsartan D9
[2H9]-Valsartan (mixture)
ACWBQPMHZXGDFX-KDDXQTGLSA-N
VALSARTAN-D9 (D7-D9 MIXTURE)
L-Valine, N-(1-oxopentyl-d9)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-
(2S)-3-methyl-2-[2,2,3,3,4,4,5,5,5-nonadeuteriopentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
Valsartan D9Q: What is
Valsartan D9 Q: What is the CAS Number of
Valsartan D9 Q: What is the storage condition of
Valsartan D9 Q: What are the applications of
Valsartan D9 | [Molecular Formula]
C24H20D9N5O3 | [MDL Number]
MFCD08063540 | [MOL File]
1089736-73-1.mol | [Molecular Weight]
444.574 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
An isotopically labelled version of Valsartan (V095750), a nonpeptide angiotensin II AT1-receptor antagonist. Antihypertensive. | [Biological Activity]
Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM). It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor γ (PPARγ) activity in vitro. In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes. Formulations containing valsartan have been used in the treatment of hypertension and heart failure. |
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|